Most Read
- Industry calls for urgent clarity on EU workers as survey shows recruitment crunch looming
- Cortec® Introduces EcoShield® Super Barrier Paper and Linerboard
- Daimler launches new DENZA electric vehicle for the Chinese market
- Rimac opens 100 new jobs
- Covestro expands global capacity for polyurethane dispersions
- Amey and Sersa, as part of the S&C North Alliance, win Infrastructure Achievement Award at National Rail Awards
- European Commission Approves Symtuza® for the Treatment of HIV-1 In Adults and Adolescents in Europe
- BNP Paribas takes further measures to accelerate its support of the energy transition
Chemicals and Pharmaceuticals
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced a new clinical collaboration with AstraZeneca to evaluate the safety and efficacy of AstraZeneca's durvalumab, a human monoclonal antibody directed against programmed death-ligand 1 (PD-L1), in combination with SNDX-6352, Syndax's monoclonal antibody inhibitor of Colony-Stimulating Factor 1 Receptor (CSF1R), across a variety of solid tumors.
Evonetix Ltd, the Cambridge-based company pioneering an innovative approach to enable scalable and high-fidelity gene synthesis, announced today that it has completed a $12.3 million financing to advance the development of its technology.
MacLellan Rubber has been working closely with their supply chain partners and can announce a breakthrough in Nitrosamine-free polymer materials.
The Dow Chemical Company (DOW) announced today that it was recognised as a 2017 Clarivate Analytics Top 100 Global Innovator for the seventh consecutive year.
Novartis recently announced a licensing agreement with Spark Therapeutics covering development, registration and commercialisation rights to voretigene neparvovec in markets outside the US.
Evonik and Siemens are planning to use electricity from renewable sources and bacteria to convert carbon dioxide into speciality chemicals.
Sanofi and Bioverativ Inc, a biopharmaceutical company focused on therapies for hemophilia and other rare blood disorders, have entered into a definitive agreement under which Sanofi will acquire all of the outstanding shares of Bioverativ for $105 per share in cash, representing an equity value of approximately $11.6 billion (on a fully diluted basis).
Honeywell Process Solutions has announced that BASF has opened a state-of-the-art control room equipped with Honeywell Experion® technology at its waste incineration complex in Ludwigshafen, Germany.